TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Cut by F M Investments LLC

F M Investments LLC lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 29.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 50,888 shares of the company's stock after selling 21,574 shares during the period. F M Investments LLC owned approximately 0.15% of TransMedics Group worth $3,173,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Arizona State Retirement System lifted its holdings in TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after buying an additional 184 shares during the period. National Bank of Canada FI raised its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after acquiring an additional 317 shares during the last quarter. Park Avenue Securities LLC grew its holdings in shares of TransMedics Group by 3.8% during the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock worth $548,000 after purchasing an additional 322 shares during the last quarter. Finally, Captrust Financial Advisors grew its holdings in TransMedics Group by 20.6% during the 3rd quarter. Captrust Financial Advisors now owns 1,988 shares of the company's stock worth $312,000 after acquiring an additional 340 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TMDX shares. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Price Performance

TransMedics Group stock traded down $0.92 during midday trading on Wednesday, reaching $86.26. 492,248 shares of the company were exchanged, compared to its average volume of 1,334,139. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of 91.77 and a beta of 2.14. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm's 50-day simple moving average is $71.46 and its 200-day simple moving average is $80.72.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.